JP2022510964A5 - - Google Patents
Info
- Publication number
- JP2022510964A5 JP2022510964A5 JP2021531128A JP2021531128A JP2022510964A5 JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5 JP 2021531128 A JP2021531128 A JP 2021531128A JP 2021531128 A JP2021531128 A JP 2021531128A JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192042A JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781689P | 2018-12-19 | 2018-12-19 | |
| US62/781,689 | 2018-12-19 | ||
| PCT/US2019/067173 WO2020132066A1 (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192042A Division JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022510964A JP2022510964A (ja) | 2022-01-28 |
| JP2022510964A5 true JP2022510964A5 (https=) | 2022-12-26 |
| JPWO2020132066A5 JPWO2020132066A5 (https=) | 2022-12-26 |
| JP7637052B2 JP7637052B2 (ja) | 2025-02-27 |
Family
ID=69182681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531128A Active JP7637052B2 (ja) | 2018-12-19 | 2019-12-18 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
| JP2024192042A Pending JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192042A Pending JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11396544B2 (https=) |
| EP (1) | EP3897715A1 (https=) |
| JP (2) | JP7637052B2 (https=) |
| KR (1) | KR20210104836A (https=) |
| CN (1) | CN113164598B (https=) |
| AU (1) | AU2019405747A1 (https=) |
| BR (1) | BR112021010238A2 (https=) |
| CA (1) | CA3124168A1 (https=) |
| CL (1) | CL2021001630A1 (https=) |
| CO (1) | CO2021009004A2 (https=) |
| EA (1) | EA202191580A1 (https=) |
| IL (1) | IL283945A (https=) |
| MA (1) | MA54540A (https=) |
| MX (1) | MX2021007497A (https=) |
| MY (1) | MY206140A (https=) |
| PH (1) | PH12021551401A1 (https=) |
| WO (1) | WO2020132066A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246514A1 (en) * | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| WO2020198009A1 (en) | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| US11905332B2 (en) | 2020-09-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof |
| KR20230098317A (ko) * | 2020-11-03 | 2023-07-03 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | 표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체 |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| IL314916A (en) | 2022-03-07 | 2024-10-01 | Novimmune Sa | Bispecific CD28 antibodies for targeted T cell activation |
| CN119095873A (zh) | 2022-03-14 | 2024-12-06 | 拉姆卡普生物伽马股份公司 | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| TW202413416A (zh) * | 2022-04-11 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| CN119546329A (zh) | 2022-04-11 | 2025-02-28 | 瑞泽恩制药公司 | 用于通用肿瘤细胞杀伤的组合物和方法 |
| CN117264065B (zh) * | 2022-06-15 | 2025-11-18 | 三优生物医药(上海)有限公司 | 一种her2抗原结合分子及其应用 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260042821A1 (en) * | 2022-10-07 | 2026-02-12 | Fred Hutchinson Cancer Center | Human metapneumovirus antibodies and uses thereof |
| WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| TW202500582A (zh) | 2023-03-13 | 2025-01-01 | 美商再生元醫藥公司 | 以雙特異性抗cd22x抗cd28分子治療癌症之方法 |
| CN120904324A (zh) * | 2024-04-30 | 2025-11-07 | 惠和生物技术(上海)有限公司 | 抗cd28抗体及其用途 |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| WO2008038587A1 (fr) * | 2006-09-25 | 2008-04-03 | National University Corporation Nagoya University | Lignée cellulaire du lymphome b malin modifié négativement par cd20 |
| US20130079353A1 (en) * | 2009-12-22 | 2013-03-28 | Karsten Gülow | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| WO2012171020A1 (en) * | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014044793A2 (en) * | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| WO2020028444A1 (en) * | 2018-07-30 | 2020-02-06 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
| CN109021114B (zh) * | 2018-08-08 | 2020-06-09 | 武汉波睿达生物科技有限公司 | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 |
| MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
-
2019
- 2019-12-18 MA MA054540A patent/MA54540A/fr unknown
- 2019-12-18 US US16/719,015 patent/US11396544B2/en active Active
- 2019-12-18 WO PCT/US2019/067173 patent/WO2020132066A1/en not_active Ceased
- 2019-12-18 CN CN201980080109.1A patent/CN113164598B/zh active Active
- 2019-12-18 MY MYPI2021003083A patent/MY206140A/en unknown
- 2019-12-18 MX MX2021007497A patent/MX2021007497A/es unknown
- 2019-12-18 BR BR112021010238-8A patent/BR112021010238A2/pt unknown
- 2019-12-18 AU AU2019405747A patent/AU2019405747A1/en active Pending
- 2019-12-18 KR KR1020217022524A patent/KR20210104836A/ko active Pending
- 2019-12-18 CA CA3124168A patent/CA3124168A1/en active Pending
- 2019-12-18 JP JP2021531128A patent/JP7637052B2/ja active Active
- 2019-12-18 EP EP19839551.9A patent/EP3897715A1/en active Pending
- 2019-12-18 PH PH1/2021/551401A patent/PH12021551401A1/en unknown
- 2019-12-18 EA EA202191580A patent/EA202191580A1/ru unknown
-
2021
- 2021-06-13 IL IL283945A patent/IL283945A/en unknown
- 2021-06-17 CL CL2021001630A patent/CL2021001630A1/es unknown
- 2021-07-08 CO CONC2021/0009004A patent/CO2021009004A2/es unknown
-
2022
- 2022-06-21 US US17/844,814 patent/US20230174652A1/en not_active Abandoned
-
2024
- 2024-10-31 JP JP2024192042A patent/JP2025013425A/ja active Pending
-
2025
- 2025-01-30 US US19/040,913 patent/US20250223360A1/en active Pending